AbbVie Inc.
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Synthroid (levothyroxine) [legacy through FY21] by Year
Synthroid (levothyroxine) [legacy through FY21] — Worldwide net revenues ($M) ($M)
AbbVie Synthroid (levothyroxine) [legacy through FY21]: $767M in FY2021, down 0.5% from a year earlier. No newer figure appears in the documents we track.
Where the FY2021 figure comes from
Source: Form 10-K (filed 2022-02-18) ↗
Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Synthroid (levothyroxine) [legacy through FY21] — Worldwide net revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2021 | Dec 31, 2021 | 767 | -0.5% | Form 10-K (filed 2022-02-18) ↗ |
| FY2020 | Dec 31, 2020 | 771 | -1.9% | Form 10-K (filed 2022-02-18) ↗ |
| FY2019 | Dec 31, 2019 | 786 | +1.3% | Form 10-K (filed 2022-02-18) ↗ |
| FY2018 | Dec 31, 2018 | 776 | -0.6% | Form 10-K (filed 2021-02-19) ↗ |
| FY2017 | Dec 31, 2017 | 781 | +2.4% | Form 10-K (filed 2018-02-16) ↗ |
| FY2016 | Dec 31, 2016 | 763 | +1.1% | Form 10-K (filed 2018-02-16) ↗ |
| FY2015 | Dec 31, 2015 | 755 | – | Form 10-K (filed 2018-02-16) ↗ |
Breakdown
What makes up synthroid (levothyroxine) [legacy through FY21]
- Synthroid (levothyroxine) [legacy through FY21] — U.S. net revenues ($M)767 · FY2021
- Synthroid (levothyroxine) [legacy through FY21] — Worldwide reported growth YoY (%)-0.6% · FY2021
- Synthroid (levothyroxine) [legacy through FY21] — Worldwide operational (constant-currency) growth YoY (%)1.3% · FY2019
Cite this data
StockData. (2026). AbbVie Synthroid (levothyroxine) [legacy through FY21] ($M), annual FY2015–FY2021 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/synthroid-ww
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.